Nishii K, Matsushita N, Sawada H, Sano H, Noda Y, Mamiya T, et al. Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. J Neurosci Res. 1998;54:450–64.
Article
CAS
PubMed
Google Scholar
Hagino Y, Kasai S, Fujita M, Setogawa S, Yamaura H, Yanagihara D, et al. Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology. 2015;40:1141–50.
Article
CAS
PubMed
Google Scholar
Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, et al. N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci USA. 2003;100:13674–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee YS, Park YS, Chang DJ, Hwang JM, Min CK, Kaang BK, et al. Cloning and expression of a G protein-linked acetylcholine receptor from Caenorhabditis elegans. J Neurochem. 1999;72:58–65.
Article
CAS
PubMed
Google Scholar
Dean B, Scarr E. Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020;288: 112989.
Article
CAS
PubMed
Google Scholar
Salah-Uddin H, Scarr E, Pavey G, Harris K, Hagan JJ, Dean B, et al. Altered M1 muscarinic acetylcholine receptor (CHRM1)-Gαq/11 coupling in a schizophrenia endophenotype. Neuropsychopharmacology. 2009;34:2156–66.
Article
CAS
PubMed
Google Scholar
Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1996;1:54–8.
CAS
PubMed
Google Scholar
Montani C, Canella C, Schwarz AJ, Li J, Gilmour G, Galbusera A, et al. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacology. 2021;46:1194–206.
Article
CAS
PubMed
Google Scholar
Crans RAJ, Wouters E, Valle-León M, Taura J, Massari CM, Fernández-Dueñas V, et al. Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders. Front Pharmacol. 2020;11:194.
Article
CAS
PubMed
PubMed Central
Google Scholar
Joseph L, Thomsen M. Effects of muscarinic receptor antagonists on cocaine discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor knockout mice. Behav Brain Res. 2017;329:75–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jeon WJ, Gibbons AS, Dean B. The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:7–12.
Article
CAS
PubMed
Google Scholar
Gibbons AS, Scarr E, Boer S, Money T, Jeon WJ, Felder C, et al. Widespread decreases in cortical muscarinic receptors in a sub-set of people with schizophrenia. Int J Neuropsychopharmacol. 2013;16:37–46.
Article
CAS
PubMed
Google Scholar
Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci. 2002;22:1709–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033–9.
Article
PubMed
Google Scholar
Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717–26.
Article
CAS
PubMed
PubMed Central
Google Scholar